Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism, a condition in which the thyroid gland produces too much of the hormone thyroxine. It is named after Robert J. Graves, an Irish physician who first described the disorder in 1835. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Symptoms of Graves’ disease can include weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland.
Graves’ disease is an autoimmune disorder in which the body’s immune system mistakenly attacks the thyroid gland. This causes the thyroid gland to produce too much of the hormone thyroxine. Too much thyroxine can lead to a number of symptoms, including weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Graves’ disease is the most common form of hyperthyroidism, and it is estimated to affect approximately 1 in 200 people.
The exact cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Studies have shown that people with Graves’ disease are more likely to have certain genetic variations, which may increase their risk of developing the disorder. Additionally, environmental factors such as stress, smoking, and certain medications may increase the risk of developing Graves’ disease.
Graves’ disease is typically diagnosed based on a physical examination and a review of the patient’s medical history. A doctor may also order blood tests to measure levels of thyroid hormones and antibodies associated with Graves’ disease. An imaging test such as an ultrasound or CT scan may be used to look for an enlarged thyroid gland.
Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. Medications such as antithyroid drugs, beta-blockers, and radioactive iodine can be used to reduce the production of thyroxine. Surgery to remove part or all of the thyroid gland is usually recommended for people with severe symptoms or those who do not respond to medications.
Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism and it is estimated to affect approximately 1 in 200 people. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. It is important for doctors to be aware of the signs and symptoms of Graves’ disease in order to properly diagnose and treat the disorder.
1.
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
2.
According to new studies, some cancer patients can safely forego radiation therapy.
3.
According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.
4.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
5.
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
1.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
2.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
3.
Community-Based Cancer Survivorship Support Systems
4.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
Navigating the Complexities of Ph Negative ALL - Part III
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation